GLIMEPIRIDE+METFORMIN+PIOGLITAZONE belongs to the group of medications called ‘antidiabetic agents’ used in the treatment of Type 2 diabetes mellitus. Type 2 diabetes mellitus is a chronic or life-long condition in which blood sugar or glucose levels rise more than normal. It occurs when the body does not produce enough insulin (metabolizes glucose), or if produced, it cannot function properly in the body.
GLIMEPIRIDE+METFORMIN+PIOGLITAZONE is a combination of three medicines, namely: Metformin, Glimepiride, and Pioglitazone. Metformin acts by decreasing liver glucose production and intestinal glucose uptake. Glimepiride acts by increasing the amount of insulin released by the pancreas. Pioglitazone works by decreasing the amount of glucose released by the liver and also by improving the sensitivity of tissues towards insulin effects.
You should take this medicine as prescribed by your doctor. You may experience side-effects of such as nausea (feeling sick), vomiting (falling sick), diarrhea, headache, stomach ache, respiratory infection, weight gain, sweating, palpitations, and vision problems. Some patients experience decline in blood sugar levels lower than normal (hypoglycemia) resulting in sweating, dizziness, headache, confusion, feeling hungry, temporary changes in vision, uneasiness, irritability, and weakness. In such cases, seek medical attention immediately.
Do not take GLIMEPIRIDE+METFORMIN+PIOGLITAZONE if you are allergic to any of its contents. Do not use this medicine if you have heart failure, bladder cancer, or diabetic ketoacidosis (a complication of diabetes). GLIMEPIRIDE+METFORMIN+PIOGLITAZONE may cause ‘lactic acidosis’ (accumulation of lactic acid in the blood), which requires immediate medical attention. The risk increases if you are previously diagnosed with kidney or liver diseases. Do not consume alcohol (risk of lactic acidosis) or fast for prolonged periods (risk of hypoglycemia). Also, inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Type 2 Diabetes Mellitus
GLIMEPIRIDE+METFORMIN+PIOGLITAZONE contains Metformin, Glimepiride, and Pioglitazone. GLIMEPIRIDE+METFORMIN+PIOGLITAZONE is given when single or dual therapy of hypoglycemic agents is not effective in diabetes patients. Metformin acts by decreasing liver glucose production and intestinal glucose uptake. Glimepiride acts by increasing the secretion of insulin by the pancreas. Pioglitazone works by decreasing the amount of glucose released by the liver and improving insulin sensitivity in muscle and fat.
GLIMEPIRIDE+METFORMIN+PIOGLITAZONE should be used with caution in patients with heart diseases as it increases the risk of heart failure. GLIMEPIRIDE+METFORMIN+PIOGLITAZONE may cause ‘lactic acidosis’ (buildup of lactic acid in the blood), characterized by abdominal pain, muscle cramps, vomiting, severe fatigue, and difficulty breathing. It is a life-threatening condition that requires immediate medical attention. Inform your doctor if you have any severe liver or kidney problems as their normal functioning is required to eliminate excess lactic acid from the body. Do not consume excess alcohol as it increases the risk of lactic acidosis. GLIMEPIRIDE+METFORMIN+PIOGLITAZONE may lower vitamin B12 levels, so it is recommended to take blood tests regularly to identify any vitamin deficiencies.
Drug-Drug interactions: GLIMEPIRIDE+METFORMIN+PIOGLITAZONE may have an interaction with medicines used to treat bacterial infections (rifampicin, tetracycline, and clarithromycin), a medicine used to treat fungal infections (fluconazole), other oral antidiabetics, and medicines used to treat gout (probenecid).
Drug-Food interactions: Intake of excess alcohol may increase the chance of a life-threatening condition known as lactic acidosis.
Drug-Disease interactions: GLIMEPIRIDE+METFORMIN+PIOGLITAZONE should be avoided in patients with heart diseases (congestive heart failure and myocardial infarction), vitamin B12 deficiency, and alcoholism, type I diabetes, bladder cancer, edema (fluid retention), liver disease, premenopausal anovulation, obesity (weight gain), anemia should avoid intake of GLIMEPIRIDE+METFORMIN+PIOGLITAZONE.
Alcohol may increase the risk of side-effects and worsen the condition.
GLIMEPIRIDE+METFORMIN+PIOGLITAZONE is a category C drug and may cause harmful effects to the unborn baby. So, it is used only when the benefits of this medicine outweigh the risks.
GLIMEPIRIDE+METFORMIN+PIOGLITAZONE should not be used in breastfeeding mothers as it may get secreted in the breast milk and cause unwanted effects in the nursing babies.
GLIMEPIRIDE+METFORMIN+PIOGLITAZONE may cause vision problems. So, do not drive or operate heavy machinery if you have any problems with your vision while using GLIMEPIRIDE+METFORMIN+PIOGLITAZONE.
GLIMEPIRIDE+METFORMIN+PIOGLITAZONE should be taken with caution in patients with liver diseases. The dose may have to be adjusted by your doctor.
GLIMEPIRIDE+METFORMIN+PIOGLITAZONE should be taken with caution especially if you have a history of kidney diseases. The dose may have to be adjusted by your doctor.
GLIMEPIRIDE+METFORMIN+PIOGLITAZONE is not recommended for use in children below 18 years of age.
Type 2 diabetes mellitus: It is a chronic condition in which blood glucose levels are elevated in the body. Insulin is responsible for the utilization of glucose by the cells. In type 2 diabetes, the body cells do not respond to insulin, or in later stages, your body may not produce enough insulin. Symptoms include excessive thirst, excessive hunger, fatigue, increased appetite, and dry mouth. This condition may worsen over time and cause toxic effects if not properly treated.
Gemer P2 Tablet 10's
₹155.8 (MRP 177)12%Off
Triglynase 2 Tablet 10's
₹75.7 (MRP 86)12%Off
Tribet 2 Tablet 15's
₹264.9 (MRP 301)12%Off
Gluconorm PG 2 Tablet 15's
₹279.8 (MRP 318)12%Off